Old and new serological biomarkers in melanoma: Where we are in 2009

Melanoma Research

Volumn 20, Issue 2, 2010, Pages 67-76

  Mouawad, Roger ^a   Spano, Jean Philippe ^a   Khayat, David ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Melanoma; Predictive factors; Prognostic factors; Serological biomarkers

Indexed keywords

BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHITINASE; FAS ANTIGEN; FAS LIGAND; GALECTIN 3; GELATINASE B; HLA ANTIGEN CLASS 1; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; LACTATE DEHYDROGENASE; MELAN A; MELANOMA INHIBITORY ACTIVITY PROTEIN; MONOPHENOL MONOOXYGENASE; PROTEIN S 100; PROTEIN YKL 40; SOLUBLE INTERLEUKIN 2 RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR ANTIGEN; TUMOR ASSOCIATED ANTIGEN 90 IMMUNE COMPLEX; TUMOR PROTEIN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 3;

ANTIGEN ANTIBODY COMPLEX; APOPTOSIS; BODY FLUID; CANCER CLASSIFICATION; CANCER INVASION; CANCER MORPHOLOGY; CANCER TISSUE; CELL ADHESION; CLINICAL TRIAL; HISTOPATHOLOGY; HUMAN; MELANOMA; MELANOMA CELL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEOMICS; REVIEW; SEROLOGY; TREATMENT RESPONSE; TUMOR VOLUME;

HUMANS; MELANOMA; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77949556502     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328335a8c1     Document Type: Review

References (108)

1. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-3648.
2. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol 2003; 21:43-52.
3. Pons M, Mancheno-Corvo P, Martin-Duque P, Quintanilla M. Molecular biology of malignant melanoma. Adv Exp Med Biol 2008; 624:252-264.
4. Lomas J, Martin-Duque P, Pons M, Quintanilla M. The genetics of malignant melanoma. Front Biosci 2008; 13:5071-5093.
5. Deichmann M, Benner A, Bock M, Jackel A, Uhl K, Waldmann V, et al. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 1999; 17:1891-1896.
6. Franzke A, Probst-Kepper M, Buer J, Duensing S, Hoffmann R, Wittke F, et al. Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. Br J Cancer 1998; 78:40-45.
7. Martenson ED, Hansson LO, Nilsson B, von Schoultz E, Mansson Brahme E, Ringborg U, et al. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. J Clin Oncol 2001; 19:824-831.
8. Schultz ES, Diepgen TL, Von Den Driesch P. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma. Br J Dermatol 1998; 138:426-430.
9. Hauschild A, Engel G, Brenner W, Glaser R, Monig H, Henze E, et al. S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 1999; 56:338-344.
10. Buer J, Probst M, Franzke A, Duensing S, Haindl J, Volkenandt M, et al. Elevated serum levels of S100 and survival in metastatic malignant melanoma. Br J Cancer 1997; 75:1373-1376.
11. Tarhini AA, Stuckert J, Lee S, Sander C, Kirkwood JM. Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol 2009; 27:38-44.
12. Bosserhoff AK, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R, et al. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 1997; 57:3149-3153.
13. Bosserhoff AK, Dreau D, Hein R, Landthaler M, Holder WD, Buettner R. Melanoma inhibitory activity MIA. a serological marker of malignant melanoma. Recent Results Cancer Res 2001; 158:158-168.
14. Juergensen A, Holzapfel U, Hein R, Stolz W, Buettner R, Bosserhoff A. Comparison of two prognostic markers for malignant melanoma: MIA and S100 beta. Tumour Biol 2001; 22:54-58.
15. Mouawad R, Benhammouda A, Rixe O, Antoine EC, Borel C, Weil M, et al. Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden. Clin Cancer Res 1996; 2:1405-1409.
16. Mouawad R, Rixe O, Meric JB, Khayat D, Soubrane C. Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study. Cytokines Cell Mol Ther 2002; 7:151-156.
17. Soubrane C, Rixe O, Meric JB, Khayat D, Mouawad R. Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study. Melanoma Res 2005; 15:199-204.
18. Tas F, Oguz H, Argon A, Duranyildiz D, Camlica H, Yasasever V, et al. The value of serum levels of IL-6, TNF-alpha, and erythropoietin in metastatic malignant melanoma: serum IL-6 level is a valuable prognostic factor at least as serum LDH in advanced melanoma. Med Oncol 2005; 22:241-246.
19. Boyano MD, Garcia-Vazquez MD, Gardeazabal J, Garcia de Galdeano A, Smith-Zubiaga I, Canavate ML, et al. Serum-soluble IL-2 receptor and IL-6 levels in patients with melanoma. Oncology 1997; 54:400-406.
20. Ottaiano A, Leonardi E, Simeone E, Ascierto PA, Scala S, Calemma R, et al. Soluble interleukin-2 receptor in stage I-III melanoma. Cytokine 2006; 33:150-155.
21. Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 2002; 4:250-255.
22. Tartour E, Dorval T, Mosseri V, Deneux L, Mathiot C, Brailly H, et al. Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer 1994; 69:911-913.
23. Deichmann M, Benner A, Waldmann V, Bock M, Jackel A, Naher H. Interleukin-6 and its surrogate C-reactive protein are useful serum markers for monitoring metastasized malignant melanoma. J Exp Clin Cancer Res 2000; 19:301-307.
24. Deichmann M, Kahle B, Moser K,Wacker J,Wust K. Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase. Br J Cancer 2004; 91:699-702.
25. Hsueh EC, Gupta RK, Qi K, Morton DL. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol 1998; 16:2913-2920.
26. Hsueh EC, Gupta RK, Qi K, Yee R, Leopoldo ZC, Morton DL. TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma. Cancer J Sci Am 1997; 3:364-370.
27. Kelley MC, Gupta RK, Hsueh EC, Yee R, Stern S, Morton DL. Tumor-associated antigen TA90 immune complex assay predicts recurrence and survival after surgical treatment of stage I-III melanoma. J Clin Oncol 2001; 19:1176-1182.
28. Faries MB, Gupta RK, Ye X, Lee C, Yee R, Leopoldo Z, et al. A Comparison of 3 tumor markers MIA, TA90IC, S100B in stage III melanoma patients. Cancer Invest 2007; 25:285-293.
29. Schmidt H, Johansen JS, Sjoegren P, Christensen IJ, Sorensen BS, Fode K, et al. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J Clin Oncol 2006; 24:798-804.
30. Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, von der Maase H. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer 2006; 106:1130-1139.
31. Vereecken P, Awada A, Suciu S, Castro G, Morandini R, Litynska A, et al. Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients. Melanoma Res. 2009; 19:316-320.
32. Rebmann V, Ugurel S, Tilgen W, Reinhold U, Grosse-Wilde H. Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients. Int J Cancer 2002; 100:580-585.
33. Westhoff U, Fox C, Otto FJ. Soluble HLA class I antigens in plasma of patients with malignant melanoma. Anticancer Res 1998; 18:3789-3792.
34. Cao MG, Auge JM, Molina R, Marti R, Carrera C, Castel T, et al. Melanoma inhibiting activity protein (MIA), beta-2 microglobulin and lactate dehydrogenase LDH in metastatic melanoma. Anticancer Res 2007; 27:595-599.
35. Nikkola J, Vihinen P, Vuoristo MS, Kellokumpu-Lehtinen P, Kahari VM, Pyrhonen S. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res 2005; 11:5158-5166.
36. Yoshino Y, Kageshita T, Nakajima M, Funakubo M, Ihn H. Clinical relevance of serum levels of matrix metallopeptidase-2, and tissue inhibitor of metalloproteinase-1 and -2 in patients with malignant melanoma. J Dermatol 2008; 35:206-214.
37. Ugurel S, Rappl G, TilgenW, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001; 19:577-583.
38. Soubrane C, Mouawad R, Rixe O, Spano J-P, Gatineau M, Khayat D. Changes in circulating VEGF-A levels related to clinical response during biochemotherapy in metastatic malignant melanoma. J Clin Oncol Meeting Abstracts.2004; 22:7531.
39. Mouawad R, Soubrane C, Khayat D. Prognostic relevance of pretreatment soluble vascular endothelial growth factors (A, C, D) and their receptors (R1, R2, and R3).in advanced melanoma patients. J Clin Oncol Meeting Abstracts. 2007; 25:8540.
40. Mouawad R, Spano JP, Comperat E, Capron F, Khayat D. Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome. Eur J Cancer 2009; 45:1407-1414.
41. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. Clin Cancer Res 2001; 7:1282-1286.
42. Mouawad R, Khayat D, Soubrane C. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma. Melanoma Res 2000; 10:461-467.
43. Vuoristo MS, Laine S, Huhtala H, Parvinen LM, Hahka-Kemppinen M, Korpela M, et al. Serum adhesion molecules and interleukin-2 receptor as markers of tumour load and prognosis in advanced cutaneous melanoma. Eur J Cancer 2001; 37:1629-1634.
44. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients. Melanoma Res 2006; 16:405-411.
45. Mellado B, Del Carmen Vela M, Colomer D, Gutierrez L, Castel T, Quinto L, et al. Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon. J Clin Oncol 2002; 20:4032-4039.
46. Osella-Abate S, Savoia P, Cambieri I, Salomone B, Quaglino P, Bernengo MG. Role of RT-PCR tyrosinase detection in the monitoring of patients with advanced metastatic melanoma. Melanoma Res 2000; 10:545-555.
47. Osella-Abate S, Savoia P, Quaglino P, Fierro MT, Leporati C, Ortoncelli M, et al. Tyrosinase expression in the peripheral blood of stage III melanoma patients is associated with a poor prognosis: a clinical follow-up study of 110 patients. Br J Cancer 2003; 89:1457-1462.
48. Curry BJ, Myers K, Hersey P. Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment, and recurrence from melanoma. J Clin Oncol 1998; 16:1760-1769.
49. Findeisen P, Zapatka M, Peccerella T, Matzk H, Neumaier M, Schadendorf D, et al. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling. J Clin Oncol 2009; 27:2199-2208.
50. Hill BR, Levi C. Elevation of a serum component in neoplastic disease. Cancer Res 1954; 14:513-515.
51. Campora E, Repetto L, Giuntini P, Bertelli G, Amoroso D, Sertoli MR, et al. LDH in the follow-up of stage I malignant melanoma. Eur J Cancer Clin Oncol 1988; 24:277-278.
52. Finck SJ, Giuliano AE, Morton DL. LDH and melanoma. Cancer 1983; 51:840-843.
53. Gaynor R, Irie R, Morton D, Herschman HR. S100 protein is present in cultured human malignant melanomas. Nature 1980; 286:400-401.
54. Cochran AJ, Holland GN, Wen DR, Herschman HR, Lee WR, Foos RY, et al. Detection of cytoplasmic S-100 protein in primary and metastatic intraocular melanomas. Invest Ophthalmol Vis Sci 1983; 24:1153-1155.
55. Cochran AJ, Wen DR, Herschman HR, Gaynor RB. Detection of S-100 protein as an aid to the identification of melanocytic tumors. Int J Cancer 1982; 30:295-297.
56. Abraha HD, Fuller LC, Du Vivier AW, Higgins EM, Sherwood RA. Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma. Br J Dermatol 1997; 137:381-385.
57. Guo HB, Stoffel-Wagner B, Bierwirth T, Mezger J, Klingmuller D. Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer 1995; 31A: 1898-1902.
58. Von Schoultz E, Hansson LO, Djureen E, Hansson J, Karnell R, Nilsson B, et al. Prognostic value of serum analyses of S-100 beta protein in malignant melanoma. Melanoma Res 1996; 6:133-137.
59. Vrbic S, Filipovic S, Pejic I, Vrbic M, Filipovic A. Sensitivity, specificity, positive and negative predictive value of serum S-100 beta protein in patients with malignant melanoma. J BUON 2003; 8:139-141.
60. Hauschild A, Engel G, Brenner W, Glaser R, Monig H, Henze E, et al. Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br J Dermatol 1999; 140:1065-1071.
61. Mocellin S, Zavagno G, Nitti D. The prognostic value of serum S100B in patients with cutaneous melanoma: a meta-analysis. Int J Cancer 2008; 123:2370-2376.
62. Apfel R, Lottspeich F, Hoppe J, Behl C, Durr G, Bogdahn U. Purification and analysis of growth regulating proteins secreted by a human melanoma cell line. Melanoma Res 1992; 2:327-336.
63. Blesch A, Bosserhoff AK, Apfel R, Behl C, Hessdoerfer B, Schmitt A, et al. Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res 1994; 54:5695-5701.
64. Bogdahn U, Apfel R, Hahn M, Gerlach M, Behl C, Hoppe J, et al. Autocrine tumor cell growth-inhibiting activities from human malignant melanoma. Cancer Res 1989; 49:5358-5363.
65. Djukanovic D, Hofmann U, Sucker A, Rittgen W, Schadendorf D. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma. Anticancer Res 2000; 20:2203-2207.
66. Bosserhoff AK. Melanoma inhibitory activity (MIA): an important molecule in melanoma development and progression. Pigment Cell Res 2005; 18:411-416.
67. Krahn G, Kaskel P, Sander S,Waizenhofer PJ,Wortmann S, Leiter U, et al. S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase. Anticancer Res 2001; 21:1311-1316.
68. Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T, Brocker EB. Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res 1995; 5:67-68.
69. Nemunaitis J, Fong T, Shabe P, Martineau D, Ando D. Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest 2001; 19:239-247.
70. Mouawad R, Khayat D, Merle S, Antoine EC, Gil-Delgado M, Soubrane C. Is there any relationship between interleukin-6/interleukin-6 receptor modulation and endogenous interleukin-6 release in metastatic malignant melanoma patients treated by biochemotherapy? Melanoma Res 1999; 9:181-188.
71. Rote NS, Gupta RK, Morton DL. Tumor-associated antigens detected by autologous sera in urine of patients with solid neoplasms. J Surg Res 1980; 29:18-22.
72. Bussink AP, Speijer D, Aerts JM, Boot RG. Evolution of mammalian chitinase(-like) members of family 18 glycosyl hydrolases. Genetics 2007; 177:959-970.
73. Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 2006; 15:194-202.
74. Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E, Iacobelli S. Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res 2000; 6:1389-1393.
75. Vereecken P, Heenen M. Serum galectin-3 in advanced melanoma patients: a hypothesis on a possible role in melanoma progression and inflammation. J Int Med Res 2006; 34:119-120.
76. Vereecken P, Zouaoui Boudjeltia K, Debray C, Awada A, Legssyer I, Sales F, et al. High serum galectin-3 in advanced melanoma: preliminary results. Clin Exp Dermatol 2006; 31:105-109.
77. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2:161-174.
78. Redondo P, Lloret P, Idoate M, Inoges S. Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression. Clin Exp Dermatol 2005; 30:541-545.
79. Tas F, Duranyildiz D, Oguz H, Disci R, Kurul S, Yasasever V, et al. Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in patients with malignant melanoma. Med Oncol 2005; 22:39-44.
80. Osella-Abate S, Quaglino P, Savoia P, Leporati C, Comessatti A, Bernengo MG. VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course. Melanoma Res 2002; 12:325-334.
81. Pelletier F, Bermont L, Puzenat E, Blanc D, Cairey-Remonnay S, Mougin C, et al. Circulating vascular endothelial growth factor in cutaneous malignant melanoma. Br J Dermatol 2005; 152:685-689.
82. Hirai S, Kageshita T, Kimura T, Tsujisaki M, Imai K, Wakamatsu K, et al. Serum levels of sICAM-1 and 5-S-cysteinyldopa as markers of melanoma progression. Melanoma Res 1997; 7:58-62.
83. Krasagakis K, Tholke D, Farthmann B, Eberle J, Mansmann U, Orfanos CE. Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma. Br J Cancer 1998; 77:1492-1494.
84. Kounalakis N, Goydos JS. Tumor cell and circulating markers in melanoma: diagnosis, prognosis, and management. Curr Oncol Rep 2005; 7:377-382.
85. Reinhold U, Ludtke-Handjery HC, Schnautz S, Kreysel HW, Abken H. The analysis of tyrosinase-specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression. J Invest Dermatol 1997; 108:166-169.
86. Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991; 338:1227-1229.
87. Brossart P, Schmier JW, Kruger S,Willhauck M, Scheibenbogen C, Mohler T, et al. A polymerase chain reaction-based semiquantitative assessment of malignant melanoma cells in peripheral blood. Cancer Res 1995; 55:4065-4068.
88. Carrillo E, Prados J, Marchal JA, Boulaiz H, Martinez A, Rodriguez-Serrano F, et al. Prognostic value of RT-PCR tyrosinase detection in peripheral blood of melanoma patients. Dis Markers 2006; 22:175-181.
89. Curry BJ, Myers K, Hersey P. Utility of tests for circulating melanoma cells in identifying patients who develop recurrent melanoma. Recent Results Cancer Res 2001; 158:211-230.
90. Jung FA, Buzaid AC, Ross MI,Woods KV, Lee JJ, Albitar M, et al. Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. J Clin Oncol 1997; 15:2826-2831.
91. Keilholz U. New prognostic factors in melanoma: mRNA tumour markers. Eur J Cancer 1998; 34 (Suppl 3):S37-S41.
92. Battayani Z, Grob JJ, Xerri L, Noe C, Zarour H, Houvaeneghel G, et al. Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma. Arch Dermatol 1995; 131:443-447.
93. Tessier MH, Denis MG, Lustenberger P, Dreno B. Detection of circulating neoplastic cells by reverse transcriptase and polymerase chain reaction in melanoma. Ann Dermatol Venereol 1997; 124:607-611.
94. Quaglino P, Osella-Abate S, Cappello N, Ortoncelli M, Nardo T, Fierro MT, et al. Prognostic relevance of baseline and sequential peripheral blood tyrosinase expression in 200 consecutive advanced metastatic melanoma patients. Melanoma Res 2007; 17:75-82.
95. Quaglino P, Savoia P, Fierro MT, Osella-Abate S, Bernengo MG. Clinical significance of sequential tyrosinase expression in the peripheral blood of disease-free melanoma patients: a review of literature data. Melanoma Res 2004; 14:S17-S19.
96. Hoon DS, Wang Y, Dale PS, Conrad AJ, Schmid P, Garrison D, et al. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 1995; 13:2109-2116.
97. Schittek B, Blaheta HJ, Florchinger G, Sauer B, Garbe C. Increased sensitivity for the detection of malignant melanoma cells in peripheral blood using an improved protocol for reverse transcription-polymerase chain reaction. Br J Dermatol 1999; 141:37-43.
98. Schittek B, Bodingbauer Y, Ellwanger U, Blaheta HJ, Garbe C. Amplification of MelanA messenger RNA in addition to tyrosinase increases sensitivity of melanoma cell detection in peripheral blood and is associated with the clinical stage and prognosis of malignant melanoma. Br J Dermatol 1999; 141:30-36.
99. Curry BJ, Myers K, Hersey P. MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastases. J Clin Oncol 1999; 17:2562-2571.
100. Schrader AJ, Probst-Kepper M, Grosse J, Kunter U, Franzke A, Sel S, et al. Tumour microdissemination and survival in metastatic melanoma. Anticancer Res 2000; 20:3619-3624.
101. Schrader AJ, Probst-Kepper M, Grosse J, Kunter U, Schenk F, Franzke A, et al. Molecular and prognostic classification of advanced melanoma: a multi-marker microcontamination assay of peripheral blood stem cells. Melanoma Res 2000; 10:355-362.
102. Palmieri G, Ascierto PA, Perrone F, Satriano SM, Ottaiano A, Daponte A, et al. Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. J Clin Oncol 2003; 21:767-773.
103. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006; 354:709-718.
104. Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L,Winans MT, et al. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res 2007; 13:2422-2428.
105. Hamberg AP, Korse CM, Bonfrer JM, de Gast GC. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma. Melanoma Res 2003; 13:45-49.
106. Soubrane C, Mouawad R, Ichen M, Suissa J, Borel C, Vuillemin E, et al. Follow up of soluble IL-2 receptor level in metastatic malignant melanoma patients treated by chemoimmunotherapy. Clin Exp Immunol 1994; 95:232-236.
107. Sabatino M, Kim-Schulze S, Panelli MC, Stroncek D, Wang E, Taback B, et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol 2009; 27:2645-2652.
108. Mian S, Ugurel S, Parkinson E, Schlenzka I, Dryden I, Lancashire L, et al. Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J Clin Oncol 2005; 23:5088-5093.